CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Antitumor Activity of Lanreotide Autogel 120 mg in Enteropancreatic Neuroendocrine Tumour (NET) Patients: The Clarinet Open-Label Extension Study
DOI 10.1055/s-0035-1559246
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Pavel, M Caplin, JB Ćwikła, A Phan, M Raderer, E Sedláčková, G Cadiot, E Wolin, J Capdevila, L Wall, G Rindi, A Langley, E Gomez-Panzani, P Ruszniewski
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: CLARINET core study data has demonstrated the efficacy and safety/tolerability of lanreotide as an antitumor treatment in patients with metastatic enteropancreatic NETs. Here, we report updated PFS data and safety findings from the CLARINET open-label extension (OLE; NCT00842348). Methods: In the core study, patients with metastatic well/moderately differentiated non-functioning enteropancreatic NETs,…
Zitieren
Zitierempfehlung
M Pavel, M Caplin, JB Ćwikła, A Phan, M Raderer, E Sedláčková, G Cadiot, E Wolin, J Capdevila, L Wall, G Rindi, A Langley, E Gomez-Panzani, P Ruszniewski (2015) Antitumor Activity of Lanreotide Autogel 120 mg in Enteropancreatic Neuroendocrine Tumour (NET) Patients: The Clarinet Open-Label Extension Study. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0035-1559246
Mit CareLit weiterarbeiten